Vaccines
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines
Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21
FDA Halts Pediatric RSV Vaccine Trials Due to Safety Concerns
RSV vaccines, pediatric trials, safety concerns, FDA hold, VAERD risk
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership
GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure
GSK, HBV, therapeutic vaccine, efficacy failure, clinical trial termination
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy
FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination